Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (7)
  • Open Access

    ARTICLE

    Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway

    Wenliang Tan*†1, Sicong Zhu*†1, Jun Cao*†, Lei Zhang*†, Wenda Li*†, Kairui Liu*†, Jinyi Zhong, Changzhen Shang*†, Yajin Chen*†

    Oncology Research, Vol.25, No.9, pp. 1543-1553, 2017, DOI:10.3727/096504017X14886444100783

    Abstract Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib is necessary to improve the antitumor efficiency. Here we demonstrated that expression of MMP-2 is positively correlated with the migration ability of HCC cells. Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive to sorafenib than those with lower MMP-2 expression (HepG2 cells). Cotreatment of cells with SB-3CT and sorafenib more strongly inhibited… More >

  • Open Access

    ARTICLE

    Blue LED promotes the chemosensitivity of human hepatoma to Sorafenib by inducing DNA damage

    TONG WANG1,4,#, JINHUAN HONG1,5,#, JIAJIE XIE1,5, QIAN LIU4, JINRUI YUE1,5, XUTING HE1,5, SHIYU GE4, TAO LI4, GUOXIN LIU4, BENZHI CAI1,3,5, LINQIANG LI2,*, YE YUAN1,3,5,*

    BIOCELL, Vol.47, No.8, pp. 1811-1820, 2023, DOI:10.32604/biocell.2023.029120

    Abstract Background: Phototherapies based on sunlight, infrared, ultraviolet, visible, and laser-based treatments present advantages like high curative effects, small invasion, and negligible adverse reactions in cancer treatment. We aimed to explore the potential therapeutic effects of blue light emitting diode (LED) in human hepatoma cells and decipher the underlying cellular and molecular mechanisms. Methods: Wound healing and transwell assays were employed to probe the inhibition of the invasion and migration of hepatocellular carcinoma cells in the presence of blue LED. The sphere-forming test was used to evaluate the effect of LED blue light irradiation on cancer… More > Graphic Abstract

    Blue LED promotes the chemosensitivity of human hepatoma to Sorafenib by inducing DNA damage

  • Open Access

    ARTICLE

    Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells

    Dong Li*1, Fei-fan Sun*1, Dan Wang*1, Tao Wang*, Jing-jing Peng*, Jian-Qiong Feng*, Hua Li*, Chao Wang, Dai-jun Zhou*, Hong Luo*, Zeng-qiang Fu*, Tao Zhang*

    Oncology Research, Vol.28, No.5, pp. 467-481, 2020, DOI:10.3727/096504020X15925659763817

    Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug… More >

  • Open Access

    ERRATUM

    Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells

    Dong Li*1, Fei-fan Sun*1, Dan Wang*1,Tao Wang*, Jing-jing Peng*, Jian-Qiong Feng*, Hua Li*, Chao Wang, Dai-jun Zhou*, Hong Luo*, Zeng-qiang Fu*, Tao Zhang*

    Oncology Research, Vol.28, No.7-8, pp. 827-828, 2020, DOI:10.3727/096504021X16280937554409

    Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug… More >

  • Open Access

    ARTICLE

    Exploration of Combinational Therapeutic Strategies for HCC Based on TCGA HCC Database

    Dong Yan1,#, Chunxiao Li2,#, Yantong Zhou2, Xue Yan1, Weihua Zhi1, Haili Qian2,*, Yue Han1,*

    Oncologie, Vol.24, No.1, pp. 101-111, 2022, DOI:10.32604/oncologie.2022.020357

    Abstract Hepatocellular carcinoma (HCC) is one of the most deadly types of cancer. Sorafenib is currently the only available first-line molecular targeted drug approved by the FDA for HCC. However, primary and secondary resistance is often encountered with treatment with sorafenib. Genomic alterations found in HCC represent potential targets to develop new drugs or new combinational strategies against this type of cancer. Here we analyzed genomic alterations from the TCGA database of HCC samples and the corresponding targeted drugs available to the clinic to identify candidate drugs that might hold promise when used in combination with… More >

  • Open Access

    ARTICLE

    LncRNA-POIR knockdown promotes hepatocellular carcinoma sensitivity to sorafenib through upregulating miR-182-5p and inhibiting autophagy

    JIAN XU1,#, HAILONG GE1,#, CHEN CHAO1, FENG MO1, YU WANG1, DENGKUI ZHANG1, XIAOXIAO ZHENG2, LI ZHENG2, XUEMEI LU2, WEI CHEN2, QUN XU1,*, WEIXIN YU1,*

    BIOCELL, Vol.46, No.6, pp. 1493-1503, 2022, DOI:10.32604/biocell.2022.016962

    Abstract Although sorafenib has been found to prolong the survival time of patients with hepatocellular carcinoma (HCC), sorafenib resistance remains an important challenge. Increasing studies have demonstrated that long noncoding RNAs (lncRNAs) contribute to drug resistance in a wide number of cancers. Human periodontal ligament stem cell (PDLSC) osteogenesis impairment-related lncRNA (POIR) is a recently defined lncRNA for which little is known regarding its function. Our study aimed to reveal the role of POIR in the development of HCC cell sorafenib resistance. The level of POIR expression in patients and tumor cells was examined by Reverse… More >

  • Open Access

    ARTICLE

    Calcium chloride linked camel milk derived casein nanoparticles for the delivery of sorafenib in hepatocarcinoma cells

    AASTHA MITTAL1, NEELAM MAHALA1, KOWTHAVARAPU VENKATA KRISHNA2, UMA S. DUBEY1,*, SUNIL KUMAR DUBEY2,3,*

    BIOCELL, Vol.46, No.1, pp. 127-136, 2022, DOI:10.32604/biocell.2021.015932

    Abstract Sorafenib, a multikinase inhibitor used for the treatment of hepatocellular carcinoma, is limited by its low oral bioavailability. To overcome this drawback, we have developed novel camel milk casein-derived nanoparticles as a drug delivery system. Camel milk casein is not only biocompatible on oral administration but is actually a dietary protein of pharmaceutical relevance. Casein is used because of its amphiphilic nature, self-assembling property, ability to show sustained release, and capability of encapsulating both hydrophilic and hydrophobic drugs. In this study, camel milk casein nanoparticles loaded with sorafenib were developed and characterized. Characterization of casein… More >

Displaying 1-10 on page 1 of 7. Per Page